Roth Capital Has Negative Estimate for Accuray Q3 Earnings

Accuray Incorporated (NASDAQ:ARAY) – Stock analysts at Roth Capital cut their Q3 2025 EPS estimates for shares of Accuray in a research note issued to investors on Wednesday, February 12th. Roth Capital analyst J. Wittes now forecasts that the medical equipment provider will post earnings per share of ($0.05) for the quarter, down from their prior forecast of $0.01. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray’s Q4 2025 earnings at $0.08 EPS.

Accuray (NASDAQ:ARAY) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%.

Separately, StockNews.com upgraded Accuray from a “hold” rating to a “buy” rating in a research report on Monday.

Accuray Trading Up 2.2 %

Shares of Accuray stock opened at $2.28 on Friday. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.87. The stock has a market capitalization of $234.45 million, a PE ratio of -45.60 and a beta of 1.51. Accuray has a 1-year low of $1.40 and a 1-year high of $2.95. The company’s fifty day simple moving average is $2.13 and its 200-day simple moving average is $1.98.

Institutional Trading of Accuray

Hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC bought a new position in Accuray in the 2nd quarter worth $30,000. US Bancorp DE lifted its position in shares of Accuray by 1,087.7% in the third quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 16,316 shares in the last quarter. Caprock Group LLC bought a new position in shares of Accuray in the third quarter worth about $36,000. Intech Investment Management LLC purchased a new stake in shares of Accuray during the third quarter worth about $41,000. Finally, Prudential Financial Inc. bought a new stake in Accuray during the 4th quarter valued at approximately $43,000. 64.08% of the stock is owned by hedge funds and other institutional investors.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.